Avanos reported a strong second quarter with positive growth in its Specialty Nutrition Systems and RFA business, supported by strategic divestitures and leadership changes. However, the quarter was also marked by significant challenges, including a large goodwill impairment charge, declines in certain business areas, and the impact of tariffs. Despite these challenges, the company reaffirmed its 2025 guidance.

Company Guidance

During the Avanos Second Quarter 2025 Earnings Conference Call, the company reaffirmed its 2025 financial guidance, projecting full-year revenue between $665 million and $685 million despite the impact of divesting the hyaluronic acid product line. They reported $175 million in net sales for the quarter, with organic sales growth of 2% compared to the previous year. The Specialty Nutrition Systems portfolio experienced a 5% organic growth, while the Pain Management and Recovery segment saw a 3.4% increase in normalized organic sales. The company also recorded an adjusted EBITDA of $17 million and adjusted diluted earnings per share of $0.17, with adjusted gross margins at 55.7% and SG&A expenses constituting 45.2% of revenue. A noncash impairment charge of $77 million was taken in the Pain Management and Recovery unit due to goodwill assessment. Additionally, Avanos anticipates $15 million in incremental tariff-related costs for the year and expects to generate approximately $40 million in free cash flow.

Strong Second Quarter Performance

Avanos delivered a strong second quarter with net sales of $175 million, organic sales up 2% compared to a year ago, and $0.17 of adjusted diluted earnings per share. Adjusted EBITDA was $17 million, with adjusted gross margins of 55.7%.

Specialty Nutrition Systems Growth

The Specialty Nutrition Systems portfolio grew 5% organically year over year, reaffirming the #1 position in long-term, short-term, and neonatal enteral feeding. The neonatal solutions business grew greater than 12% compared to the prior year.

Radiofrequency Ablation Business Success

The RFA business posted near 14% growth compared to the previous year. Sustained growth in RFA generator capital sales enabled higher procedure volumes.

Hyaluronic Acid Divestiture

Avanos closed the sale of its hyaluronic acid product line, marking a significant step in its transformation strategy focused on growth in Specialty Nutrition Systems and Pain Management and Recovery.

Leadership Appointments

Scott Galovan was appointed as the new CFO, and David Pacitti was appointed to Avanos' Board of Directors.

Avanos Medical (AVNS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AVNS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.12 / -	0.33	―	―	―
Aug 05, 2025	2025 (Q2)	0.15 / 0.17	0.29	-41.38% (-0.12)
May 06, 2025	2025 (Q1)	0.18 / 0.26	0.19	36.84% (+0.07)
Feb 26, 2025	2024 (Q4)	0.40 / 0.43	0.36	19.44% (+0.07)
Oct 30, 2024	2024 (Q3)	0.35 / 0.33	0.307	7.49% (+0.02)
Jul 31, 2024	2024 (Q2)	0.29 / 0.29	0.231	25.54% (+0.06)
May 02, 2024	2024 (Q1)	0.21 / 0.19	0.27	-29.63% (-0.08)
Feb 20, 2024	2023 (Q4)	0.37 / 0.36	0.6	-40.00% (-0.24)
Nov 01, 2023	2023 (Q3)	0.28 / 0.31	0.38	-19.21% (-0.07)
Aug 09, 2023	2023 (Q2)	0.30 / 0.23	0.41	-43.66% (-0.18)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AVNS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$11.25	$9.89	-12.09%
May 06, 2025	$12.19	$12.85	+5.41%
Feb 26, 2025	$15.56	$15.62	+0.39%
Oct 30, 2024	$22.63	$18.58	-17.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Avanos Medical (AVNS) report earnings?

Avanos Medical (AVNS) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is Avanos Medical (AVNS) earnings time?

Avanos Medical (AVNS) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AVNS EPS forecast?

AVNS EPS forecast for the fiscal quarter 2025 (Q3) is 0.12.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing